Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Larsucosterol in Primary Sclerosing Cholangitis
NCT03394781Phase 2Terminated
- Sponsor
- DURECT Corporation
- Start
- Jan 2018
- Primary completion
- Jan 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of larsucosterol in Primary Sclerosing Cholangitis (PSC), sponsored by DURECT Corporation. Started Jan 2018; status: terminated.
02
Drugs
larsucosterol
03
Conditions
Primary Sclerosing Cholangitis (PSC)
Beyond the preview
Go deeper on NCT03394781.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03394781.